Hide Board Information

Show Board Information

Global Medical REIT, Inc. GMRE

Board Mod: Add me as mod

Asst Mods:

Last Post: 09/03/2020 8:40:48 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 3

Global Medical REIT, Inc. (GMRE)<br /><br />Company Website: <br />

Global Medical REIT, Inc. (OTCMRKTS: GMRE) Stock Message Board

1. GMRE Company Profile

    

2. GMRE Time & Sales

    

3. GMRE Recent News

    

4. GMRE Filings

    

5. GMRE Financials

    

6. GMRE Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

5	$GMRE News Article - Global Medical REIT Inc.	whytestocks	09/03/2020 8:40:48 AM
4	$GMRE News Article - Global Medical REIT Inc.	whytestocks	09/13/2019 3:00:41 PM
3	$GMRE News Article - Global Medical REIT Inc.	whytestocks	06/14/2019 11:15:41 AM
2	GMRE 0.21 Stock Charts $GMRE 1 Month Chart	chartguy89	03/07/2014 12:44:43 PM
1	GMRE Stock Charts Last: +0.05 Wednesday, February	chartguy89	02/26/2014 12:48:36 PM

Recent Articles

• Legal Action Launched for Kyverna Therapeutics Investors
• Everlight Solar's Culture: A Testament to Team Camaraderie and Growth
• Haloid Enhances Safety in Film Productions with Reviews
• Insights on the Growing Demand for Edible Coatings in Produce
• Prospect Ridge Resources Adjusts Plans for Upcoming Meeting
• Legal Update: Toronto-Dominion Bank Securities Class Action
• Key Updates from Nasdaq on the Nasdaq-100 Index Changes
• TeraBox Revolutionizes File Sharing with Free Unlimited Service
• Kessler Topaz Takes Action Against Enphase Energy for Fraud
• Demesne Resources Completes Second Tranche of Financing
• Spiro Celebrated as One of the Top Agencies in Marketing
• Global Uranium Corp. Launches Strategic Marketing Efforts
• UnitedHealth Group Clarifies Misconceptions and Updates Claims
• Neurocrine Biosciences Unveils Potential of CRENESSITY™ for CAH
• Acadia Healthcare Investors Urged to Take Action on Lawsuit
• Global Uranium Corp. Unveils C$1.5 Million Flow-Through Offering
• Rakovina Therapeutics Secures $3M to Propel Cancer Therapy Advances
• Hola Prime's Innovative Vision: New Marketing Director Appointed
• Teamsters Advocate for Stronger Standards on Autonomous Vehicles
• BioVaxys Secures Funding and Enters Debt Settlement Agreement
• Exciting Advancement as UNLOXCYT Gains FDA Approval for Treatment
• OFS Credit Company Shares November Net Asset Value Insights
• New FDA Approval for Crenessity Enhances CAH Treatment Options
• Q-Gold Secures Initial Funding for New Exploration Ventures
• Capital Power's Genesee Project Marks Major Energy Milestone
• Viridian Therapeutics Set to Present Veligrotug Results Soon
• Ensuring Safe Travels: King County's Holiday Traffic Initiative
• Acadia Healthcare Faces Class Action Amid Significant Losses
• S&P Dow Jones Indices Reveals Results of 2024 DJSI Review
• Celebrating Entrepreneurial Success: The Impact of MBDA
• Village Super Market's Dividend Announcement and Growth Plans
• Digi International Welcomes New Executive Leaders to Board
• Transfusion Market Expected to Rise by $2.6 Billion: Insights
• CenterPoint Energy Announces Increased Quarterly Dividend Payout
• Shobha Launches Exciting Offers and Convenient Memberships
• ANSC Secures Key Approval for Upcoming Business Combination
• Barite Market Forecast: Growth Driven by Oil and AI Trends
• Contract Cleaning Services: Driving Growth with AI Innovation
• Lochmere Association Recognized for Eco-Friendly Excellence
• Fairholme Funds Announcement: December Dividend Details
• Empowering Change: Vigil for Clemency at the White House
• Boar's Head Reaches Settlement in Landmark Listeria Case
• Discover the SR6800 Window: Where History Meets Innovation
• Turkish Airlines Announces New Lounge at JFK's Terminal One
• AI Innovations Fuel Growth in the Analytical Standards Market
• Understanding the Seafood Market: Trends and Innovations
• Univest Securities Completes $2.7 Million Offering for LICN
• CubeSmart Declares Quarterly Dividend Increase for Shareholders
• Douglas Emmett Inc. Announces Cash Dividend for Shareholders
• Galderma's Breakthrough Approval of Nemluvio for Atopic Dermatitis